Sign in or create an account to add this stock to your watchlist.
About Immune Design (NASDAQ:IMDZ)
Immune Design Corp., a clinical-stage immunotherapy company, engages in the research and development of in vivo treatments for cancer. The company primarily develops oncology product candidates based on its ZVex and GLAAS discovery platforms. Its lead products include CMB305, a cancer vaccine targeting the NY-ESO-1 tumor antigen, which is in Phase 2 trial for the treatment of patients with synovial and MRCL sarcoma as a monotherapy; and G100, an antigen agnostic intratumoral product candidate as a monotherapy and combination therapy for the treatment of patients with follicular non-Hodgkin Lymphoma. The company is also developing CA21, a multi-targeting prime boost for the treatment of multiple solid tumors; and ZVex-IL12 for the treatment of TBD tumors. In addition, its technologies are used in the fields of infectious and allergic diseases. The company has license agreements with California Institute of Technology, University of North Carolina at Chapel Hill, TheraVectys SA, Infectious Disease Research Institute, MedImmune LLC, and Sanofi; and a collaboration agreement with Sanofi Pasteur. Immune Design Corp. was founded in 2008 and is headquartered in Seattle, Washington.
Industry, Sector and Symbol
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:IMDZ
CUSIPN/A
Phone206-682-0645
Debt
Debt-to-Equity RatioN/A
Current Ratio21.18
Quick Ratio21.08
Price-To-Earnings
Trailing P/E Ratio-2.49
Forward P/E Ratio-3.43
P/E GrowthN/A
Sales & Book Value
Annual Sales$7.20 million
Price / Sales29.08
Cash FlowN/A
Price / CashN/A
Book Value$2.90 per share
Price / Book1.50
Profitability
EPS (Most Recent Fiscal Year)($1.75)
Net Income$-51,860,000.00
Net Margins-2,352.98%
Return on Equity-52.00%
Return on Assets-45.88%
Miscellaneous
Employees56
Outstanding Shares48,130,000
Immune Design (NASDAQ:IMDZ) Frequently Asked Questions
What is Immune Design's stock symbol?
Immune Design trades on the NASDAQ under the ticker symbol "IMDZ."
How were Immune Design's earnings last quarter?
Immune Design (NASDAQ:IMDZ) released its quarterly earnings data on Wednesday, May, 2nd. The biotechnology company reported ($0.28) earnings per share for the quarter, beating the consensus estimate of ($0.29) by $0.01. The biotechnology company had revenue of $0.50 million for the quarter, compared to analyst estimates of $1.83 million. Immune Design had a negative return on equity of 52.00% and a negative net margin of 2,352.98%. View Immune Design's Earnings History.
When is Immune Design's next earnings date?
What price target have analysts set for IMDZ?
4 Wall Street analysts have issued 1 year target prices for Immune Design's stock. Their forecasts range from $8.00 to $20.00. On average, they expect Immune Design's share price to reach $12.6667 in the next twelve months. View Analyst Ratings for Immune Design.
Who are some of Immune Design's key competitors?
Some companies that are related to Immune Design include InflaRx (IFRX), Theratechnologies (THERF), Rocket Pharmaceuticals (RCKT), Dova Pharmaceuticals (DOVA), GlycoMimetics (GLYC), Amphastar Pharmaceuticals (AMPH), Vectura Group (VEGPF), ANI Pharmaceuticals Inc Common Stock (ANIP), CymaBay Therapeutics (CBAY), NuCana (NCNA), Homology Medicines (FIXX), Dicerna Pharmaceuticals (DRNA), Arcus Biosciences (RCUS), Rigel Pharmaceuticals (RIGL) and Five Prime Therapeutics (FPRX).
Who are Immune Design's key executives?
Immune Design's management team includes the folowing people:
- Dr. Carlos V. Paya M.D., Ph.D., Chief Exec. Officer, Pres and Director (Age 59)
- Mr. Stephen R. Brady J.D., LLM, Principal Financial Officer, Principal Accounting Officer and Exec. VP of Strategy & Fin. (Age 48)
- Dr. Jan Henrik Ter Meulen M.D., DR. HABIL., DTM&H, Chief Scientific Officer (Age 55)
- Mr. Christopher Whitmore CPA, VP of Fin. & Admin.
- Dr. Wayne R. Gombotz Ph.D., Chief Devel. Officer (Age 59)
Has Immune Design been receiving favorable news coverage?
News headlines about IMDZ stock have trended positive recently, according to Accern. The research firm scores the sentiment of media coverage by monitoring more than 20 million blog and news sources. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Immune Design earned a coverage optimism score of 0.28 on Accern's scale. They also gave news headlines about the biotechnology company an impact score of 44.75 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company's share price in the immediate future.
Who are Immune Design's major shareholders?
Immune Design's stock is owned by many different of institutional and retail investors. Top institutional shareholders include BVF Inc. IL (8.53%), BlackRock Inc. (3.98%), JPMorgan Chase & Co. (1.75%), Dimensional Fund Advisors LP (0.40%) and DRW Securities LLC (0.08%). Company insiders that own Immune Design stock include Carlos V Paya, Franklin M Berger, Group L P Column, Leo Guthart, Lewis W Coleman, Meulen Jan Henrik Ter, Peter Svennilson, Sergey Yurasov, Stephen R Brady and Wayne Gombotz. View Institutional Ownership Trends for Immune Design.
Which major investors are selling Immune Design stock?
IMDZ stock was sold by a variety of institutional investors in the last quarter, including JPMorgan Chase & Co.. Company insiders that have sold Immune Design company stock in the last year include Carlos V Paya, Meulen Jan Henrik Ter, Sergey Yurasov, Stephen R Brady and Wayne Gombotz. View Insider Buying and Selling for Immune Design.
Which major investors are buying Immune Design stock?
IMDZ stock was bought by a variety of institutional investors in the last quarter, including BVF Inc. IL, Dimensional Fund Advisors LP, BlackRock Inc. and DRW Securities LLC. Company insiders that have bought Immune Design stock in the last two years include Franklin M Berger, Group L P Column, Leo Guthart, Lewis W Coleman, Peter Svennilson and Stephen R Brady. View Insider Buying and Selling for Immune Design.
How do I buy shares of Immune Design?
Shares of IMDZ can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Immune Design's stock price today?
One share of IMDZ stock can currently be purchased for approximately $4.35.
How big of a company is Immune Design?
Immune Design has a market capitalization of $204.53 million and generates $7.20 million in revenue each year. The biotechnology company earns $-51,860,000.00 in net income (profit) each year or ($1.75) on an earnings per share basis. Immune Design employs 56 workers across the globe.
How can I contact Immune Design?
Immune Design's mailing address is 1616 EASTLAKE AVENUE EAST SUITE 310, SEATTLE WA, 98102. The biotechnology company can be reached via phone at 206-682-0645 or via email at [email protected]
MarketBeat Community Rating for Immune Design (IMDZ)
MarketBeat's community ratings are surveys of what our community members think about Immune Design and other stocks. Vote "Outperform" if you believe IMDZ will outperform the S&P 500 over the long term. Vote "Underperform" if you believe IMDZ will underperform the S&P 500 over the long term. You may vote once every thirty days.
Immune Design (NASDAQ:IMDZ) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
4 Wall Street analysts have issued ratings and price targets for Immune Design in the last 12 months. Their average twelve-month price target is $12.6667, suggesting that the stock has a possible upside of 191.19%. The high price target for IMDZ is $20.00 and the low price target for IMDZ is $8.00. There are currently 1 hold rating and 3 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 2.75 | 2.75 | 2.75 | 2.75 |
| Ratings Breakdown: | 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $12.6667 | $12.6667 | $16.00 | $16.00 |
| Price Target Upside: | 191.19% upside | 224.79% upside | 332.43% upside | 58.42% upside |
Immune Design (NASDAQ:IMDZ) Consensus Price Target History
Immune Design (NASDAQ:IMDZ) Analyst Ratings History
Show:
(Data available from 5/22/2016 forward)
Immune Design (NASDAQ:IMDZ) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Immune Design (NASDAQ IMDZ) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 18.10%
Institutional Ownership Percentage: 50.70%
Immune Design (NASDAQ IMDZ) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 1/8/2018 | Leo Guthart | Major Shareholder | Buy | 20,000 | $3.90 | $78,000.00 | |  |
| 1/5/2018 | Carlos V Paya | CEO | Sell | 7,970 | $4.17 | $33,234.90 | 114,560 | |
| 1/5/2018 | Meulen Jan Henrik Ter | Insider | Sell | 1,986 | $4.17 | $8,281.62 | 41,020 | |
| 1/5/2018 | Stephen R Brady | EVP | Sell | 3,328 | $4.17 | $13,877.76 | 50,490 | |
| 1/4/2018 | Sergey Yurasov | VP | Sell | 675 | $4.17 | $2,814.75 | 28,000 | |
| 11/2/2017 | Lewis W Coleman | Director | Buy | 50,000 | $4.50 | $225,000.00 | | |
| 10/30/2017 | Franklin M Berger | Director | Buy | 25,000 | $4.58 | $114,500.00 | 75,000 | |
| 10/27/2017 | Leo Guthart | Major Shareholder | Buy | 2,439,000 | $4.10 | $9,999,900.00 | | |
| 10/27/2017 | Peter Svennilson | Director | Buy | 2,681,000 | $4.10 | $10,992,100.00 | | |
| 10/25/2017 | Franklin M Berger | Director | Buy | 25,000 | $4.26 | $106,500.00 | 50,000 | |
| 10/24/2017 | Leo Guthart | Major Shareholder | Buy | 60,000 | $4.65 | $279,000.00 | | |
| 10/19/2017 | Leo Guthart | Major Shareholder | Buy | 10,000 | $6.09 | $60,900.00 | | |
| 9/18/2017 | Leo Guthart | Major Shareholder | Buy | 10,000 | $9.70 | $97,000.00 | | |
| 8/1/2017 | Wayne Gombotz | Insider | Sell | 10,000 | $11.43 | $114,300.00 | 33,054 | |
| 7/11/2017 | Lewis W Coleman | Director | Buy | 12,000 | $9.05 | $108,600.00 | 40,000 | |
| 7/10/2017 | Lewis W Coleman | Director | Buy | 10,000 | $9.00 | $90,000.00 | 40,000 | |
| 7/7/2017 | Lewis W Coleman | Director | Buy | 8,000 | $9.27 | $74,160.00 | 40,000 | |
| 1/4/2017 | Carlos V Paya | Insider | Sell | 3,940 | $5.35 | $21,079.00 | 72,000 | |
| 1/4/2017 | Stephen R Brady | EVP | Sell | 1,642 | $5.35 | $8,784.70 | 32,132 | |
| 12/22/2016 | Lewis W Coleman | Director | Sell | 10,000 | $6.20 | $62,000.00 | 40,000 | |
| 12/16/2016 | Franklin M Berger | Director | Sell | 50,000 | $6.55 | $327,500.00 | 25,000 | |
| 9/20/2016 | Group L P Column | Major Shareholder | Buy | 800,000 | $6.25 | $5,000,000.00 | | |
| 9/20/2016 | Lewis W Coleman | Director | Buy | 40,000 | $6.25 | $250,000.00 | 50,000 | |
| 7/15/2016 | Stephen R Brady | EVP | Buy | 1,500 | $6.84 | $10,260.00 | 17,132 | |
| 11/23/2015 | Wayne Gombotz | insider | Sell | 5,000 | $20.00 | $100,000.00 | 34 | |
| 9/14/2015 | Wayne Gombotz | insider | Sell | 5,000 | $16.19 | $80,950.00 | 34 | |
| 8/25/2015 | Lewis W Coleman | Director | Buy | 3,000 | $14.50 | $43,500.00 | 10,000 | |
| 5/12/2015 | Proquest Investments Iv, L.P. | Major Shareholder | Sell | 177,607 | $21.60 | $3,836,311.20 | | |
| 4/24/2015 | Proquest Investments Iv, L.P. | Major Shareholder | Sell | 82,892 | $26.81 | $2,222,334.52 | | |
| 4/21/2015 | Franklin M Berger | Director | Buy | 25,000 | $26.50 | $662,500.00 | | |
| 4/21/2015 | Proquest Investments Iv, L.P. | Major Shareholder | Sell | 45,820 | $26.51 | $1,214,688.20 | | |
| 4/16/2015 | Proquest Investments Iv, L.P. | Major Shareholder | Sell | 53,914 | $28.23 | $1,521,992.22 | | |
| 4/7/2015 | Proquest Investments Iv, L.P. | Major Shareholder | Sell | 7,495 | $26.72 | $200,266.40 | | |
| 3/25/2015 | Proquest Investments Iv, L.P. | Major Shareholder | Sell | 18,156 | $27.64 | $501,831.84 | | |
| 3/23/2015 | Proquest Investments Iv, L.P. | Major Shareholder | Sell | 44,464 | $27.52 | $1,223,649.28 | | |
| 3/18/2015 | Proquest Investments Iv, L.P. | Major Shareholder | Sell | 50,309 | $26.09 | $1,312,561.81 | | |
| 3/12/2015 | Proquest Investments Iv, L.P. | Major Shareholder | Sell | 129,342 | $24.94 | $3,225,789.48 | | |
| 3/9/2015 | Proquest Investments Iv, L.P. | Major Shareholder | Sell | 39,446 | $25.45 | $1,003,900.70 | | |
| 7/29/2014 | Alta Partners Viii, L.P. | Major Shareholder | Buy | 299,559 | $12.00 | $3,594,708.00 | | |
| 7/29/2014 | Franklin M Berger | Director | Buy | 50,000 | $12.00 | $600,000.00 | | |
(Data available from 1/1/2013 forward)
Immune Design (NASDAQ IMDZ) News Headlines
| Source: |
|
| Date | Headline |
|---|
 | Immune Design (IMDZ) Given Average Recommendation of "Buy" by Analysts
www.americanbankingnews.com - May 22 at 1:34 AM |
| Immune Design (IMDZ) Upgraded by ValuEngine to "Sell"
www.americanbankingnews.com - May 17 at 4:41 PM |
| Immune Design (IMDZ) Issues Quarterly Earnings Results
www.americanbankingnews.com - May 16 at 10:35 AM |
 | Lucky Seven: Immune Design Takes Off, Institutions Place Bets On Viking Therapeutics
seekingalpha.com - May 16 at 8:14 AM |
| Immune Design Nearing Critical Point In Valuation
seekingalpha.com - May 11 at 6:04 PM |
 | Complimentary Stock Performance Review on La Jolla Pharma and Three Additional Biotech Industry Stocks
finance.yahoo.com - May 11 at 8:16 AM |
| Immune Design (IMDZ) to Release Quarterly Earnings on Tuesday
www.americanbankingnews.com - May 8 at 2:26 AM |
| Q3 2018 EPS Estimates for Immune Design Lifted by Leerink Swann (IMDZ)
www.americanbankingnews.com - May 7 at 3:12 AM |
| Jefferies Group Equities Analysts Raise Earnings Estimates for Immune Design (IMDZ)
www.americanbankingnews.com - May 7 at 2:07 AM |
| Immune Design's (IMDZ) CEO Dr. Carlos Paya on Q1 2018 Results - Earnings Call Transcript
seekingalpha.com - May 3 at 8:10 AM |
| Immune Design: 1Q Earnings Snapshot
finance.yahoo.com - May 3 at 8:10 AM |
| Edited Transcript of IMDZ earnings conference call or presentation 2-May-18 8:30pm GMT
finance.yahoo.com - May 3 at 8:10 AM |
| Immune Design (IMDZ) Posts Earnings Results, Beats Expectations By $0.01 EPS
www.americanbankingnews.com - May 2 at 10:02 PM |
| Immune Design beats by $0.01, misses on revenue
seekingalpha.com - May 2 at 5:40 PM |
| Immune Design Reports First Quarter 2018 Financial Results and Provides Corporate Update
finance.yahoo.com - May 2 at 5:40 PM |
| Immune Design Corp (IMDZ) Given Consensus Rating of "Buy" by Brokerages
www.americanbankingnews.com - April 27 at 1:29 AM |
 | What's in the Cards for Immune Design (IMDZ) in Q1 Earnings?
www.msn.com - April 26 at 5:20 PM |
| What's in the Cards for Immune Design (IMDZ) in Q1 Earnings?
finance.yahoo.com - April 26 at 5:20 PM |
| Immune Design (IMDZ) to Release Quarterly Earnings on Wednesday
www.americanbankingnews.com - April 26 at 8:28 AM |
| Tetraphase Pharmaceuticals (TTPH) & Immune Design (IMDZ) Head-To-Head Contrast
www.americanbankingnews.com - April 25 at 11:14 PM |
| Immune Design to Report First Quarter 2018 Financial Results and Provide Corporate Update
finance.yahoo.com - April 25 at 8:13 AM |
| Why Is Immune Design (IMDZ) Down 2.7% Since Its Last Earnings Report?
finance.yahoo.com - April 13 at 5:37 PM |
| Immune Design (IMDZ) Raised to Hold at ValuEngine
www.americanbankingnews.com - April 10 at 7:51 PM |
| ValuEngine Lowers Immune Design (IMDZ) to Sell
www.americanbankingnews.com - April 8 at 11:49 AM |
| Immune Design Corp (IMDZ) Receives Consensus Recommendation of "Buy" from Brokerages
www.americanbankingnews.com - April 2 at 1:30 AM |
| Immune Design (IMDZ) Cut to "Hold" at Zacks Investment Research
www.americanbankingnews.com - March 30 at 12:34 PM |
| Immune Design Corp (NASDAQ:IMDZ): Earnings To Drop Next Year, Is It A Long-Term Trend?
finance.yahoo.com - March 22 at 8:20 AM |
| Jefferies Group Weighs in on Immune Design Corp's Q1 2018 Earnings (IMDZ)
www.americanbankingnews.com - March 19 at 1:40 AM |
| Immune Design reports 4Q loss - Yahoo Finance
finance.yahoo.com - March 17 at 8:20 AM |
| Immune Design Corp to Post FY2022 Earnings of ($0.67) Per Share, Jefferies Group Forecasts (IMDZ)
www.americanbankingnews.com - March 16 at 4:20 PM |
 | Immune Design (IMDZ) Posts Narrower-Than-Expected Loss in Q4 - Nasdaq
www.nasdaq.com - March 16 at 8:13 AM |
| Immune Design's (IMDZ) "Buy" Rating Reaffirmed at Jefferies Group
www.americanbankingnews.com - March 15 at 5:46 PM |
 | Immune Design Corp. to Host Earnings Call
www.baystreet.ca - March 14 at 7:12 PM |
| Interested In Immune Design Corp (NASDAQ:IMDZ)? Here’s How It Performed Recently
finance.yahoo.com - March 14 at 7:12 PM |
| Immune Design Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update
finance.yahoo.com - March 14 at 7:12 PM |
| $810,000.00 in Sales Expected for Immune Design Corp (IMDZ) This Quarter
www.americanbankingnews.com - March 14 at 5:02 AM |
| Immune Design (IMDZ) Upgraded by Zacks Investment Research to "Buy"
www.americanbankingnews.com - March 13 at 7:28 PM |
 | Integral Molecular’s Protein Engineering Technology Facilitates HIV Vaccine Development
www.bizjournals.com - March 13 at 7:22 PM |
 | When Corporate Social Responsibility Veers Into Political Action: Safe Or Sorry?
www.forbes.com - March 13 at 7:22 PM |
 | Immune Design (IMDZ) Announces Data Update for Lead Immunotherapy Programs
www.streetinsider.com - March 12 at 6:44 PM |
| Immune Design (IMDZ) Downgraded by Zacks Investment Research to "Hold"
www.americanbankingnews.com - March 12 at 3:14 PM |
| Immune Design Reports Data Update for Lead Immunotherapy Programs: Improvement in Survival for CMB305 Monotherapy in Sarcoma and Increased Objective Responses for G100/pembrolizumab Combination in Follicular Lymphoma
finance.yahoo.com - March 12 at 8:35 AM |
| Immune Design (IMDZ) to Release Earnings on Wednesday
www.americanbankingnews.com - March 8 at 9:47 AM |
| Immune Design Corp (IMDZ) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - March 8 at 1:24 AM |
| Immune Design to Report Fourth Quarter and Year End 2017 Financial Results and Provide Corporate Update
finance.yahoo.com - March 7 at 8:12 AM |
| Analyzing Immune Design (IMDZ) & Achaogen (AKAO)
www.americanbankingnews.com - March 5 at 11:36 AM |
 | What's Happening With These Biotech Stocks? -- Illumina, Immune Design, ImmunoCellular Therapeutics, and ... - PR Newswire (press release)
www.prnewswire.com - February 28 at 8:13 AM |
| What's in the Cards for Immune Design (IMDZ) in Q4 Earnings?
www.nasdaq.com - February 27 at 5:58 PM |
| What's in the Cards for Immune Design (IMDZ) in Q4 Earnings?
finance.yahoo.com - February 27 at 8:14 AM |
| Analysts Expect Immune Design Corp (IMDZ) Will Post Quarterly Sales of $810,000.00
www.americanbankingnews.com - February 25 at 3:48 AM |
Immune Design (NASDAQ:IMDZ) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Immune Design (NASDAQ:IMDZ) Income Statement, Balance Sheet and Cash Flow Statement
Immune Design (NASDAQ IMDZ) Stock Chart for Tuesday, May, 22, 2018
Loading chart…
